Alex Goldberg

Theravance Inc. (NASDAQ:THRX) and MannKind Corp. (NASDAQ:MNKD) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 06/23/2013 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Theravance Inc. (NASDAQ:THRX) and MannKind Corp. (NASDAQ:MNKD).

Theravance Inc. (NASDAQ:THRX) a biopharmaceutical company that engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system/pain closed up in its previous session (+10.18%) on 4,060,040 shares traded after THERAVANCE INC Filed SEC form 8-K, Other Events. Theravance Inc. (NASDAQ:THRX) is currently up (+95.72%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Theravance Inc. (NASDAQ:THRX)

MannKind Corp. (NASDAQ:MNKD) a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States closed up in its previous session (+0.37%) on 14,703,289 shares traded after MannKind Completed Afrezza Studies. MannKind Corp. (NASDAQ:MNKD) is currently up (+278.02%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about MannKind Corp. (NASDAQ:MNKD)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com